Hospira Inc.(HSP) has initiated a nationwide voluntary recall of one lot of Hydromorphone Hydrochloride Injection 1 mg/ml, with the knowledge of the FDA, after it was found that the opioid analgesic injection contained more than the intended fill volume.
The recalled product is a prefilled glass cartridge for use with Carpuject Syringe system. The affected lot number is 07547LL, which has an expiration date of July 1, 2013.
The FDA in a statement said that opioid pain medications such as Hydromorphone have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), low blood pressure and reduced heart rate including circulatory collapse.
The affected lot was distributed last September and October, initially to wholesalers and a limited number of hospitals in Alaska, Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Indiana, Louisiana, Maryland, Massachusetts, Minnesota, Missouri, Mississippi, North Carolina, New Hampshire, New Jersey, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Tennessee, Texas, Utah, Washington, and Wisconsin.
There have been no reports of adverse events related to the recalled lot, Hospira said.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.